Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab or Calcium Augmentation for Major Depressive Disorder
NCT04156425Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Jul 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
01
Overview
Randomised, double-blind trial of golimumab and calcium in major depressive disorder (MDD), sponsored by Shanghai Mental Health Center. Primary endpoint: Remission of acute phase at 12 weeks. Status: unknown.
02
Drugs
golimumabcalcium
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04156425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156425.